Tender Offer - NOVARTIS AG

Form Type: SC TO-C

Filing Date: 2025-04-30

Corporate Action: Tender-offer

Type: New

Accession Number: 000110465925042639

Filing Summary: Novartis AG, through its wholly owned subsidiary Redwood Merger Sub Inc., has filed a Tender Offer Statement with the SEC regarding its planned acquisition of all outstanding shares of Regulus Therapeutics Inc. This filing comes as part of an Agreement and Plan of Merger dated April 29, 2025. The tender offer is for all shares of Regulus's common stock, with the date of commencement not yet specified. The document indicates that further materials will be available when the offer is formally initiated. Importantly, this tender offer is characterized as a third-party tender offer subject to Rule 14d-1, and investors are advised to consult the upcoming tender offer materials and solicitation/recommendation statements for complete information. Several forward-looking statements are included regarding the potential success of the acquisition and related risks, including regulatory approvals and market conditions. The overall communication provides a framework for investors to understand the impending acquisition efforts by Novartis.